A Phase IIa, two-part, randomised, multi-centre, multinational, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of BCT197 when added on to standard of care for the treatment of acute respiratory exacerbations o

    Project: Other project

    Project Details

    StatusFinished
    Effective start/end date6/15/166/14/18

    Funding

    • ICON Clinical Research LLC: $8,126.93